Abstract
FA is a rare, multi-organ cancer-prone IBMFS associated with
hematological malignancies and STs. The androgen therapy, hematopoietic
growth factors, HSCT, and GT, still in the clinical trial, are various
treatments for this disease. Here, we aimed to compare the advantages
and disadvantages of HSCT and GT in FA cures. We perform an advanced
electronic search of “FA” AND (genetics OR treatment OR HSCT OR GT OR
Mosaicism), and “Allo-HSCT” AND (conditioning regimen OR complications
OR GvHD OR infection OR cost) MeSH terms in non-citation and citation
databases. Besides, the gray literature was searched too. This article
will provide a summary of the advantages and disadvantages of HSCT and
GT of FA disease. Our results show that GT has a good potential in FA
treatments in the future. Furthermore, it has higher advantages and
fewer disadvantages in comparison with HSCT. Systematic Review
Registration: CRD42021247364 ID on PROSPERO database.